INTRODUCTION
Renal cell carcinoma (RCC) is the third most common genitourinary tract malignancy in US men, with estimates of approximately 65,000 new cases of renal tumors and approximately 15,000 deaths in 2018. 1 Despite early detection in patients without evident metastasis, the incidence of pathologic node-positive disease ranges from 2% to 10% with a poor 5-year survival rate ranging from 5% to 30%. [2] [3] [4] [5] The tumor size, Fuhrman nuclear grade, tumor histology, performance status, and surrounding fat invasion are well-known prognostic factors; however, lymph node (LN) metastasis also plays a key role in the survival of patients with locally advanced RCC. 5, 6 According to the seventh edition 7 and recently published eighth edition 8 of the American Joint Committee on Cancer (AJCC) TNM staging manual, stage III includes 2 groups of patients: those with a primary tumor status (pT 3 ) and those with pathologic LN involvement (pN 1 ). Our hypothesis was that patients with pathologic node-positive disease should be reclassified as having stage IV disease. Our aim was to compare the outcomes of patients with stage III, node-positive disease (pT 123 N 1 M 0 ) with those of patients with stage III, node-negative disease (pT 3 N 0 M 0 ) and patients with stage IV disease.
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MATERIALS AND METHODS

Data Acquisition
The University of Texas MD Anderson Cancer Center institutional review board approved the study. The records of 4652 patients with RCC of any histological subtype who underwent radical or partial nephrectomy between 1993 and 2012 were reviewed. For stage III patients, we excluded those who did not undergo retroperitoneal LN dissection (pN x ). LN dissection was performed in 1497 patients at the discretion of the urologic surgeon. Genitourinary pathologists reviewed all surgical specimens. The study included a total of 912 patients-389 patients with stage III disease (115 patients with pT 123 N 1 M 0 disease and 274 patients with pT 3 N 0 M 0 disease) and 523 patients with stage IV disease (pT 123 N 0/x M 1 ) -to compare the outcomes of patients with stage III disease and patients with stage IV disease.
Multiple demographic and preoperative variables were collected (Table 1 ). Symptoms at initial presentation were categorized as local or systemic. Local symptoms included flank pain and hematuria, whereas systemic symptoms include fever, fatigue, night sweats, respiratory or gastrointestinal symptoms, and weight loss greater than 10 pounds. In general, clinically positive nodal disease was defined by regional lymphadenopathy greater than 1.0 cm on preoperative cross-sectional imaging or suspicious nodes found intraoperatively. Clinical and pathologic TNM staging followed the eighth edition of the 2018 AJCC staging system. 8 The tumor grade was based on the Fuhrman nuclear grading system, and the presence of a sarcomatoid component with the percentage was also recorded when available. Pathologic nodal parameters included the number of nodes removed, number of positive nodes, and presence of extranodal extension. When an individual nodal mass could not be assessed because of a confluent outline, the pathologist termed the mass matted. All postoperative radiographic studies and follow-up physician notes were independently reviewed; this included thoracic and abdominal imaging along with physical examinations and serum chemistry studies within 3 months of surgery and then every 6 months for 2 years with subsequent studies at least annually to date the recurrence accurately. If a recurrence was present, the type (local and/or distant) was recorded. Local recurrence was defined as the development of a new mass on postoperative imaging in the nephrectomy bed or the retroperitoneum.
Statistical Analysis
Patient characteristics are summarized with frequencies and percentages for categorical variables and with medians and ranges for continuous variables. The chi-square test and the Wilcoxon rank-sum test were performed to assess the difference between pT 123 N 1 M 0 and pT 3 N 0 M 0 or between pT 123 N 1 M 0 and pT 123 N 0/x M 1 in terms of categorical and continuous variables, respectively. Overall survival (OS) was defined as the time interval between the date of nephrectomy and the date of death due to any cause. Patients who were alive were censored at the last follow-up date. Cancer-specific survival (CSS) was defined as the time interval between the date of nephrectomy and the date of death due to cancer. Patients who died of other causes were censored at the death date, and those who were alive were censored at the last follow-up date. Patients who were alive and without disease recurrence were censored at the last follow-up date. The probabilities of OS and CSS were estimated with the Kaplan-Meier method. Log-rank tests were used to compare OS and CSS between subgroups of patients. Univariate Cox models were fit for OS and CSS, and variables with P values < .10 in the univariate analysis were initially included in the multivariate model. Backward model selection was then performed until all covariates remaining in the multivariate model were statistically significant with a P value < .05. All statistical analyses were conducted with SAS and S-Plus.
RESULTS
Patient Characteristics
Of the 912 patients, 389 had stage III disease (274 with pT 3 There was a significant difference among the 3 groups in CSS (P < .0001); however, similarly to OS, there was no significant difference in CSS (P = .10) between patients with stage III, node-positive disease and patients with stage IV disease. Table 4 shows that the presence of tumor grade 4 (HR, 2.99; P < .0001) and node-positive disease (HR, 2.85; P < .0001) were significantly associated with an increased risk of death due to cancer. Supporting Table 1 shows a summary of OS and CSS for all patients (n = 912).
DISCUSSION
Pathologic staging for RCC is essential for guiding postoperative surveillance and selecting patients for potential adjuvant systemic therapy. It is, therefore, critical to apply a staging system that accurately reflects the risk of RCC progression or death from the disease. We sought to define the impact on survival of pathologic LN involvement 
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80. 2 Five-year CSS rates range from 25% to 40% in contemporary studies. [9] [10] [11] Even in the targeted therapy era, adjuvant therapy with tyrosine kinase inhibitors does not appear to improve on these outcomes in patients with pN-positive disease. 12 In a Surveillance, Epidemiology, and End Results-based analysis of patients with nonmetastatic RCC, the rate of pathologic LN involvement was 11% overall. 13 The 5-year CSS rate was 38.4% for T any pN 1 patients and 83.8% for T any pN 0 patients (P < .001). In a subgroup analysis of patients with pT3 tumors, those with pN1 disease had worse 5-year CSS than those with pN0 disease (31.1% vs 69.8%; P < .001). Worse CSS was seen for pN1 patients across all pathologic T stages. These results are in keeping with our finding that LN involvement is associated with worse survival outcomes. The 5-year OS and CSS rates for pN1 patients in our cohort were 35% and 39%, respectively. A more recent study examined long-term outcomes after nephrectomy in 138 patients with LN-positive disease and no evidence of distant metastases. 11 Survival outcomes were notably poor in this population, with 10-year CSS and OS rates of 21% and 15%, respectively. The median time to the development of metastatic disease was 4.2 months, with only 37% of patients remaining free of RCC metastases 1 year after nephrectomy.
Other studies have directly compared the outcomes of patients with nonmetastatic, LN-positive RCC with the outcomes of patients with distant metastases. Pantuck et al 14 examined outcomes for 900 patients who underwent nephrectomy for RCC; on final pathology, 236 (26%) had pT any N 0 M 1 disease, and 43 (4.8%) had pT any N 1 M 0 disease. OS was not different between the 2 groups. Compared with our study, this cohort had a significantly smaller proportion of N1M0 patients, and it included pT4 tumors. A subsequent study of 171 patients with RCC treated with nephrectomy estimated the 5-and 10-year CSS probabilities for T any N 1 M 0 patients to be 39.3% and 30.5%, respectively. 15 The survival of this cohort was significantly worse than the survival of T any N 0 M 0 patients. In contrast to our findings, the survival of patients with node-positive disease (pT any N 1 M 0 ) in this study was significantly better than the survival of those with metastatic disease (pT any N 0-1 M 1 ). Two important differences between this study and our current work may explain these findings. First, we compared patients with stage III disease (pT 1-3 N 1 M 0 ) with patients who were classified as having stage IV disease strictly because of the presence of distant metastases (pT 1-3 N 0/x M 1 ) without LN involvement. Second, our cohort excluded pT4 patients and thereby provided a more direct comparison between patients with stage III, LN-positive disease and patients with stage IV, distant metastatic disease.
In the multivariate analysis, we confirmed the prognostic role of LN involvement specifically for patients with stage III RCC. Pathologic LN involvement was associated with a 2.8-fold higher risk of dying of RCC in comparison with patients with pN0 disease (95% CI, 2.0-3.9; P < .0001). This is consistent with the study by Sun et al, 13 who reported that the risk of cancer-specific mortality was 3.4-fold for pN1 disease after nephrectomy. However, their model encompassed all pathologic T stages and was not specific to stage III disease.
The current AJCC staging manual (the eighth edition) incorporates locally advanced (pT3a-c), LN-negative tumors and LN-positive disease into the same stage III grouping. 8 The results reported herein suggest that it may be prudent to revise the current staging system by classifying pN1 patients as having stage IV disease. Locally advanced RCC tumors are known to be heterogeneous, and the TNM staging system has undergone previous revisions to improve its prognostic accuracy. Thompson Cancer October 15, 2018 showed that tumors classified as pT3 because of contiguous ipsilateral adrenal gland invasion had CSS outcomes that were not significantly different from the outcomes of pT4 tumors. This facilitated the reclassification of ipsilateral adrenal invasion from pT3 to pT4 disease in the 2010 AJCC TNM staging manual (seventh edition). 7 Several authors have shown that the concomitant presence of a renal vein tumor thrombus and extrarenal fat invasion is associated with worse survival and have thus proposed a revision to the staging of pT3 tumors. 17, 18 More recently, RCC tumors with urinary collecting system invasion have been shown to be independently associated with worse OS and CSS outcomes in locally advanced tumors. [19] [20] [21] Tumors with urinary collecting system invasion are now classified as stage pT3a in the eighth edition of the AJCC staging manual. 8 If our results are validated by other studies, we recommend reclassifying patients with pN1 disease as having stage IV disease instead of stage III disease. To our knowledge, this is the first study to recommend such a reclassification in RCC.
There are several limitations to this study, including the retrospective design and inherent selection bias attributed to the high-risk patient referral pattern at our tertiary treatment center. Moreover, LN dissection templates were not standardized among all surgeons and varied in their extent and utilization over the 2 decades of data collection. Although it is not standard practice at our center to perform a template LN dissection, especially for patients without clinical evidence of nodal involvement, all clinically positive nodes in addition to suspicious nodal tissue in the appropriate landing zones are routinely resected at the time of nephrectomy. Despite these limitations, our data are reflective of a large cohort with substantial follow-up.
In conclusion, the outcomes of patients with stage III RCC due to pathologic nodal involvement are significantly worse than the outcomes of patients with stage III RCC without nodal involvement and similar to the outcomes of patients with stage IV RCC. If these findings are validated in other studies, consideration should be given to reclassifying patients with stage III, pN1 disease as having stage IV disease.
FUNDING SUPPORT
The Biostatistics Resource Group is supported by the National Institutes for Health/National Cancer Institute under award P30CA016. Kai-Jie Yu was supported in part by the Chang Gung Memorial Hospital Institute (project CMRPG3B1531). The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health (grant P30 CA016672).
